An Observational Study Investigating the Safety and Effectiveness of Repaglinide in Chinese Patients (SAFE)

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: repaglinide

Study type: Observational

Funder types: Industry

Identifiers

NCT01077570

AGEE-3822

U1111-1112-6394 (Other Identifier)

Details and patient eligibility

About

This study is conducted in Asia. The aim of this observational study is, under normal clinical practice conditions, to investigate the clinical safety and effectiveness in Chinese patients with type 2 diabetes who have never received anti-diabetic treatment before.

Enrollment: 2,033 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HbA1c more than 6.5%, no anti-diabetes treatment accepted before entering the study

Exclusion criteria

• Subjects who received any anti-diabetic treatment previously
• Known or suspected allergy to trial product(s) or related products.
• Subjects who previously enrolled in this study.
• Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods.

Trial design

2,033 participants in 1 patient group

Repaglinide

Treatment:

Drug: repaglinide